BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 34280256)

  • 1. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.
    Greinacher A; Selleng K; Mayerle J; Palankar R; Wesche J; Reiche S; Aebischer A; Warkentin TE; Muenchhoff M; Hellmuth JC; Keppler OT; Duerschmied D; Lother A; Rieg S; Gawaz MP; Mueller KAL; Scheer CS; Napp M; Hahnenkamp K; Lucchese G; Vogelgesang A; Flöel A; Lovreglio P; Stufano A; Marschalek R; Thiele T;
    Blood; 2021 Oct; 138(14):1269-1277. PubMed ID: 34280256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.
    Greinacher A; Selleng K; Palankar R; Wesche J; Handtke S; Wolff M; Aurich K; Lalk M; Methling K; Völker U; Hentschker C; Michalik S; Steil L; Reder A; Schönborn L; Beer M; Franzke K; Büttner A; Fehse B; Stavrou EX; Rangaswamy C; Mailer RK; Englert H; Frye M; Thiele T; Kochanek S; Krutzke L; Siegerist F; Endlich N; Warkentin TE; Renné T
    Blood; 2021 Dec; 138(22):2256-2268. PubMed ID: 34587242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia.
    Huynh A; Arnold DM; Ivetic N; Clare R; Hadzi-Tosev M; Liu Y; Smith JW; Bissola AL; Daka M; Kelton JG; Nazy I
    J Thromb Haemost; 2023 Oct; 21(10):2833-2843. PubMed ID: 37394121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.
    McGonagle D; De Marco G; Bridgewood C
    J Autoimmun; 2021 Jul; 121():102662. PubMed ID: 34051613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine.
    van der Neut Kolfschoten M; Inganäs H; Perez-Peinado C; Calado da Silva Freire J; Melchers JM; van Dijk N; Przeradzka M; Kourkouta E; van Manen D; Vellinga J; Custers J; Bos R
    J Thromb Haemost; 2024 Apr; 22(4):1046-1055. PubMed ID: 38159648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
    Greinacher A; Thiele T; Warkentin TE; Weisser K; Kyrle PA; Eichinger S
    N Engl J Med; 2021 Jun; 384(22):2092-2101. PubMed ID: 33835769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential mechanisms of vaccine-induced thrombosis.
    Marietta M; Coluccio V; Luppi M
    Eur J Intern Med; 2022 Nov; 105():1-7. PubMed ID: 35953336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond.
    Greinacher A; Warkentin TE
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):1-10. PubMed ID: 38066843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Aspects of VITT.
    Schönborn L; Greinacher A
    Semin Hematol; 2022 Apr; 59(2):108-114. PubMed ID: 35512899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncommon thrombotic complications after SARS-CoV-2 vaccination.
    Musil D
    Vnitr Lek; 2021; 67(5):297-302. PubMed ID: 35459396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis.
    Passariello M; Vetrei C; Amato F; De Lorenzo C
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT).
    Greinacher A; Schönborn L; Siegerist F; Steil L; Palankar R; Handtke S; Reder A; Thiele T; Aurich K; Methling K; Lalk M; Völker U; Endlich N
    Semin Hematol; 2022 Apr; 59(2):97-107. PubMed ID: 35512907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies.
    Kanack AJ; Singh B; George G; Gundabolu K; Koepsell SA; Abou-Ismail MY; Moser KA; Smock KJ; Green D; Major A; Chan CW; Wool GD; Reding M; Ashrani AA; Bayas A; Grill DE; Padmanabhan A
    Am J Hematol; 2022 May; 97(5):519-526. PubMed ID: 35132672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome in vaccine-induced immune thrombocytopenia and thrombosis.
    Schönborn L; Seck SE; Thiele T; Kaderali L; Hoffmann T; Hlinka A; Lindhoff-Last E; Völker U; Selleng K; Buoninfante A; Cavaleri M; Greinacher A
    J Thromb Haemost; 2023 Sep; 21(9):2519-2527. PubMed ID: 37394120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination.
    Lee AYY; Al Moosawi M; Peterson EA; McCracken RK; Wong SKW; Nicolson H; Chan V; Smith T; Wong MP; Lee LJ; Griffiths C; Rahal B; Parkin S; Afra K; Ambler K; Chen LYC; Field TS; Lindsay HC; Lavoie M; Li C; Migneault D; Naus M; Piszczek J; Rahmani P; Sreenivasan G; Wan T; Yee A; Zypchen L; Sweet D
    Blood Adv; 2022 Jun; 6(11):3315-3320. PubMed ID: 35201292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia.
    Huynh A; Kelton JG; Arnold DM; Daka M; Nazy I
    Nature; 2021 Aug; 596(7873):565-569. PubMed ID: 34233346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination.
    Handtke S; Wolff M; Zaninetti C; Wesche J; Schönborn L; Aurich K; Ulm L; Hübner NO; Becker K; Thiele T; Greinacher A
    Blood; 2021 Jul; 137(26):3656-3659. PubMed ID: 33945605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient.
    Schönborn L; Thiele T; Kaderali L; Günther A; Hoffmann T; Seck SE; Selleng K; Greinacher A
    Blood; 2022 Mar; 139(12):1903-1907. PubMed ID: 35113987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explaining COVID-19 postvaccination-related immune thrombotic thrombocytopenia: a hypothesis-generating
    Konstantinou GN
    Hum Vaccin Immunother; 2022 Nov; 18(5):2050654. PubMed ID: 35412949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative interpretation of PF4/heparin-EIA optical densities in predicting platelet-activating VITT antibodies.
    Schönborn L; Thiele T; Esefeld M; El Debuch K; Wesche J; Seck SE; Kaderali L; Wolff M; Warkentin TE; Greinacher A
    J Thromb Haemost; 2022 Nov; 20(11):2579-2586. PubMed ID: 36006172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.